Compare VALN & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | BWAY |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | France | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.3M | 578.5M |
| IPO Year | 2021 | 2011 |
| Metric | VALN | BWAY |
|---|---|---|
| Price | $6.69 | $13.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $15.50 | $13.25 |
| AVG Volume (30 Days) | 81.9K | ★ 107.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | $93.87 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $11.77 |
| 52 Week High | $12.23 | $26.63 |
| Indicator | VALN | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 41.95 |
| Support Level | $5.10 | $13.98 |
| Resistance Level | $7.31 | $14.83 |
| Average True Range (ATR) | 0.23 | 0.46 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 47.78 | 13.36 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.